Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2020’, provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)

– The report reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects

– The report assesses Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

ABL Bio Inc

ACEA Therapeutics Inc

Acepodia Biotech Inc

Acerta Pharma BV

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

Aeglea BioTherapeutics Inc

AgenTus Therapeutics Inc

Agenus Inc

AI Therapeutics Inc

Anew Oncology Inc

Apotex Inc

Aprea Therapeutics Inc

Ascenta Therapeutics Inc

Ascentage Pharma Group International

AstraZeneca Plc

AVM Biotechnology LLC

Bantam Pharmaceutical LLC

Bayer AG

BeiGene Ltd

Beijing GD Initiative Cell Therapy Technology Co Ltd

Beijing Mabworks Biotech Co Ltd

Table of Contents

Table of Contents

Introduction

Chronic Lymphocytic Leukemia- Overview

Chronic Lymphocytic Leukemia- Therapeutics Development

Chronic Lymphocytic Leukemia- Therapeutics Assessment

Chronic Lymphocytic Leukemia- Companies Involved in Therapeutics Development

Chronic Lymphocytic Leukemia- Drug Profiles

Chronic Lymphocytic Leukemia- Dormant Projects

Chronic Lymphocytic Leukemia- Discontinued Products

Chronic Lymphocytic Leukemia- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by 4SC AG, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AbbVie Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ABL Bio Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ACEA Therapeutics Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Acepodia Biotech Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Acerta Pharma BV, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Actinium Pharmaceuticals Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ADC Therapeutics SA, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aeglea BioTherapeutics Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AgenTus Therapeutics Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Agenus Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AI Therapeutics Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Anew Oncology Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Apotex Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aprea Therapeutics Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ascenta Therapeutics Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ascentage Pharma Group International, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AstraZeneca Plc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AVM Biotechnology LLC, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bantam Pharmaceutical LLC, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bayer AG, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by BeiGene Ltd, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Beijing GD Initiative Cell Therapy Technology Co Ltd, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by BendaRx Corp, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bio-Path Holdings Inc, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by BioIntegrator Ltd, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bionomics Ltd, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Pipeline by BioNTech SE, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H2 2020

Chronic Lymphocytic Leukemia (CLL) – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports